Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 9-14
DOI: 10.4103/ijmpo.ijmpo_29_19
Editorial Commentary

Indian council of medical research consensus document for the management of pancreatic cancer

Shailesh V Shrikhande
Tata Memorial Centre, Mumbai, Maharashtra, India
,
Savio Barreto
Tata Memorial Centre, Mumbai, Maharashtra, India
,
Bhawna Sirohi
Max Institute of Cancer Care, New Delhi, India
,
Munita Bal
Tata Memorial Centre, Mumbai, Maharashtra, India
,
Raj Kumar Shrimali
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Raju T Chacko
Department of Medical Oncology, Division of Non-Communicable Diseases, Christian Medical College, Vellore, Tamil Nadu, India
,
Vikram Chaudhari
Tata Memorial Centre, Mumbai, Maharashtra, India
,
Vikram Bhatia
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Suyash Kulkarni
Tata Memorial Centre, Mumbai, Maharashtra, India
,
Tanvir Kaur
Department of Gatroenterology, Indian Council of Medical Research, New Delhi, India
,
R S Dhaliwal
Department of Gatroenterology, Indian Council of Medical Research, New Delhi, India
,
Goura Kishor Rath
Department of Gatroenterology, Indian Council of Medical Research, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Executive Summary

This consensus document may be used as framework for more focused and planned research programs to carry forward the process. The aim of the Indian Council of Medical Research (ICMR) Guidelines is to assist oncologists in making major clinical decisions encountered while managing their patients and while realizing the fact that some patients may require treatment strategies other than those suggested in these guidelines.

  • Histological confirmation is mandatory before the commencement of definitive treatment

  • All patients should be staged according to the tumor, node, and metastasis staging system, and risk should be assessed at diagnosis. A baseline contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis should be considered

  • Patients should receive multidisciplinary care under the care of a surgical, medical, and radiation oncologist

  • The indication for endobiliary stenting in patients with obstructive jaundice includes symptoms of cholangitis and/or sepsis, resultant coagulopathy and/or renal insufficiency, or if significant delays in surgery are anticipated

  • The patient's malignancy should be classified as resectable, borderline resectable, or locally advanced on the basis of radiologic criteria at diagnosis and treatment plan discussed accordingly

  • Resectable pancreatic cancer – Primary surgery remains the standard of care. Neoadjuvant therapy (NAT) (chemotherapy ± radiotherapy) should be considered in locally advanced and borderline resectable tumors to downstage the disease followed by reassessment for surgery in those with stable or partial regression radiological criteria. This may be followed by adjuvant chemotherapy

  • Patients with metastatic disease that has spread beyond regional lymph nodes should be assessed for chemotherapy versus best supportive care on an individual basis

  • Preferred first-line regimens for chemotherapy include Gemcitabine nab-paclitaxel and FOLFIRINOX

  • Patients should be offered regular surveillance after completion of curative resection or treatment of advanced disease

  • Encourage participation in institutional and ethical review board-approved, registered clinical trials

  • Refer for early palliative care, if indicated.



Publication History

Article published online:
08 June 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403
    CrossrefPubMedGoogle Scholar
  • 2 A Snapshot of Pancreatic Cancer – National Cancer Institute; 2016. Available from: http://www.cancer.gov/research/progress/snapshots/pancreatic. [Last accessed on 2018 Dec 30].
  • 3 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30
    CrossrefPubMedGoogle Scholar
  • 4 World Wide Cancer Statistics; 2016. Available from: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data. [Last accessed on 2016 Jul 05].
  • 5 Shrikhande SV, Barreto SG, Somashekar BA, Suradkar K, Shetty GS, Talole S. et al. Evolution of pancreatoduodenectomy in a tertiary cancer center in India: Improved results from service reconfiguration. Pancreatology 2013; 13: 63-71
    CrossrefPubMedGoogle Scholar
  • 6 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
    CrossrefPubMedGoogle Scholar
  • 7 Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. J Gastroenterol 1999; 18: 24-8
    Google Scholar
  • 8 Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev 2010; 11: 1045-9
    PubMedGoogle Scholar
  • 9 Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D. et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5: v56-68
    CrossrefPubMedGoogle Scholar
  • 10 Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW. et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15: 1028-61
    CrossrefPubMedGoogle Scholar
  • 12 Watanabe H, Kanematsu M, Tanaka K, Osada S, Tomita H, Hara A. et al. Fibrosis and postoperative fistula of the pancreas: Correlation with MR imaging findings – Preliminary results. Radiology 2014; 270: 791-9
    CrossrefPubMedGoogle Scholar
  • 12 Yardimci S, Kara YB, Tuney D, Attaallah W, Ugurlu MU, Dulundu E. et al. A simple method to evaluate whether pancreas texture can be used to predict pancreatic fistula risk after pancreatoduodenectomy. J Gastrointest Surg 2015; 19: 1625-31
    CrossrefPubMedGoogle Scholar
  • 13 Lee SE, Jang JY, Lim CS, Kang MJ, Kim SH, Kim MA. et al. Measurement of pancreatic fat by magnetic resonance imaging: Predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. Ann Surg 2010; 251: 932-6
    CrossrefPubMedGoogle Scholar
  • 14 Kakar S, Pawlik T, Allen P. Exocrine pancreas. Pancreatic adenocarcinoma. In: Amin M, editor. AJCC Cancer Staging Manual. 8th ed. New York: Springer-Verlag; 2016.
  • 15 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma Version 2.2015. National Comprehensive Cancer Network; 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. [Last accessed on 2015 Apr 11].
  • 16 Barreto S, Windsor J. Palliation of extra-hepatic biliary malignancies: Diminishing role for surgery. Clin Oncol 2017; 2: 1229
    Google Scholar
  • 17 Buettner S, Wilson A, Margonis GA, Gani F, Ethun CG. et al. Assessing trends in palliative surgery for extrahepatic biliary malignancies: A 15-year multicenter study. J Gastrointest Surg 2016; 20: 1444-52
    CrossrefPubMedGoogle Scholar
  • 18 Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. et al. The value of splenic preservation with distal pancreatectomy. Arch Surg 2002; 137: 164-8
    CrossrefPubMedGoogle Scholar
  • 19 Iqbal N, Lovegrove RE, Tilney HS, Abraham AT, Bhattacharya S, Tekkis PP. et al. A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: A meta-analysis of 1909 patients. Eur J Surg Oncol 2009; 35: 79-86
    CrossrefPubMedGoogle Scholar
  • 20 Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, Friess H. et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007; 94: 265-73
    CrossrefPubMedGoogle Scholar
  • 21 Hüttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW. et al. Pylorus-preserving pancreaticoduodenectomy (pp whipple) versus pancreaticoduodenectomy (classic whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016; 2: CD006053
    PubMedGoogle Scholar
  • 22 Barreto SG. Classical or pylorus-preserving pancreatoduodenectomy in pancreatic and periampullary cancer: “The jury is still out!” Indian. J Med Paediatr Oncol 2016; 37: 209-10
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Barreto SG, Shukla PJ. Different types of pancreatico-enteric anastomosis. Transl Gastroenterol Hepatol 2017; 2: 89
    CrossrefPubMedGoogle Scholar
  • 24 Imamura M, Kimura Y, Ito T, Nobuoka T, Mizuguchi T. et al. Effects of antecolic versus retrocolic reconstruction for gastro/duodenojejunostomy on delayed gastric emptying after pancreatoduodenectomy: A systematic review and meta-analysis. J Surg Res 2016; 200: 147-57
    CrossrefPubMedGoogle Scholar
  • 25 Qu H, Sun GR, Zhou SQ, Zhou SQ. Clinical risk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: A systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 213-23
    CrossrefPubMedGoogle Scholar
  • 26 Su AP, Cao SS, Zhang Y, Zhang ZD, Hu WM, Tian BL. et al. Does antecolic reconstruction for duodenojejunostomy improve delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy? A systematic review and meta-analysis. World J Gastroenterol 2012; 18: 6315-23
    CrossrefPubMedGoogle Scholar
  • 27 Barreto SG, Windsor JA. Does the ileal brake contribute to delayed gastric emptying after pancreatoduodenectomy?. Dig Dis Sci 2017; 62: 319-35
    CrossrefPubMedGoogle Scholar
  • 28 Mitra A, Pai E, Dusane R, Ranganathan P, DeSouza A, Goel M. et al. Extended pancreatectomy as defined by the ISGPS: Useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors. Langenbecks Arch Surg 2018; 403: 203-12
    PubMedGoogle Scholar
  • 29 Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence. World J Gastrointest Surg 2010; 2: 39-46
    CrossrefPubMedGoogle Scholar
  • 30 Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. et al. En bloc resection for locally advanced cancer of the pancreas: Is it worthwhile?. J Gastrointest Surg 2002; 6: 147-57
    CrossrefPubMedGoogle Scholar
  • 31 Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?. J Gastrointest Surg 2003; 7: 946-52
    CrossrefPubMedGoogle Scholar
  • 32 Barreto SG, Pandanaboyana S, Ironside N, Windsor JA. et al. Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma?. A meta-analysis. HPB (Oxford) 2017; 19: 573-9
    CrossrefPubMedGoogle Scholar
  • 33 Kendrick ML, Cusati D. Total laparoscopic pancreaticoduodenectomy: Feasibility and outcome in an early experience. Arch Surg 2010; 145: 19-23
    CrossrefPubMedGoogle Scholar
  • 34 Palanivelu C, Rajan PS, Rangarajan M, Vaithiswaran V, Parthasarathi R. et al. Evolution in techniques of laparoscopic pancreaticoduodenectomy: A decade long experience from a tertiary center. J Hepatobiliary Pancreat Surg 2009; 16: 731-40
    CrossrefPubMedGoogle Scholar
  • 35 Ammori BJ. Laparoscopic hand-assisted pancreaticoduodenectomy: Initial UK experience. Surg Endosc 2004; 18: 717-8
    CrossrefPubMedGoogle Scholar
  • 36 Staudacher C, Orsenigo E, Baccari P, Di Palo S, Crippa S. Laparoscopic assisted duodenopancreatectomy. Surg Endosc 2005; 19: 352-6
    CrossrefPubMedGoogle Scholar
  • 37 Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB. et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-46
    CrossrefPubMedGoogle Scholar
  • 38 Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS. et al. Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the American Pancreatic Association. Gastroenterology 2014; 146: 291-3040
    CrossrefPubMedGoogle Scholar
  • 39 Callery MP, Chang KJ, Fishman EK, Talamonti MS, William TraversoL, Linehan DC. et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-33
    CrossrefPubMedGoogle Scholar
  • 40 Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP. et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-95
    CrossrefPubMedGoogle Scholar
  • 41 Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES. et al. Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 703-13
    CrossrefPubMedGoogle Scholar
  • 42 Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H. et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-46
    CrossrefPubMedGoogle Scholar
  • 43 Barreto SG, Windsor JA. Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 2016; 17: e118-24
    CrossrefPubMedGoogle Scholar
  • 44 Windsor JA, Barreto SG. The concept of 'borderline resectable' pancreatic cancer: Limited foundations and limited future?. J Gastrointest Oncol 2017; 8: 189-93
    CrossrefPubMedGoogle Scholar
  • 45 Tucker ON, Rela M. Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement. HPB Surg 2008; 2008: 839503
    CrossrefPubMedGoogle Scholar
  • 46 Shrikhande SV, Arya S, Barreto SG, Ingle S, D'Souza MA, Hawaldar R. et al. Borderline resectable pancreatic tumors: Is there a need for further refinement of this stage?. Hepatobiliary Pancreat Dis Int 2011; 10: 319-24
    CrossrefPubMedGoogle Scholar
  • 47 Barreto SG, Loveday B, Windsor JA, Pandanaboyana S. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg. 2018. doi: 10.1111/ans.14764. [Epub ahead of print].
  • 48 Kato H, Usui M, Isaji S, Nagakawa T, Wada K, Unno M. et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: A multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013; 20: 601-10
    CrossrefPubMedGoogle Scholar
  • 49 Ravikumar R, Holroyd D, Fusai G. Is there a role for arterial reconstruction in surgery for pancreatic cancer?. World J Gastrointest Surg 2013; 5: 27-9
    CrossrefPubMedGoogle Scholar
  • 50 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V. et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies. Pancreas 2015; 44: 515-21
    CrossrefPubMedGoogle Scholar
  • 51 Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C. et al. Locally advanced pancreatic cancer: Neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 2016; 264: 457-63
    CrossrefPubMedGoogle Scholar
  • 52 Ausania F, Vallance AE, Manas DM, Prentis JM, Snowden CP, White SA. et al. Double bypass for inoperable pancreatic malignancy at laparotomy: Postoperative complications and long-term outcome. Ann R Coll Surg Engl 2012; 94: 563-8
    CrossrefPubMedGoogle Scholar
  • 53 Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev 2013;(2):CD008533. doi: 10.1002/14651858.CD008533.pub3.
  • 54 Hüser N, Michalski CW, Schuster T, Friess H, Kleeff J. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. Br J Surg 2009; 96: 711-9
    CrossrefPubMedGoogle Scholar
  • 55 Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10
    CrossrefPubMedGoogle Scholar
  • 56 Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010; 304: 1073-81
    CrossrefPubMedGoogle Scholar
  • 57 Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. et al. Neonatal. Neonat 2013; 2: 4-7
    Google Scholar
  • 58 Conroy T, Hammel P, Hebbar M. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol 2018; 36: 18_suppl-LBA4001
    CrossrefGoogle Scholar